FDA Provides Emergency Use Authorization to PerkinElmer for COVID-19 Testing

Food and Healthcare Press Releases Thursday March 26, 2020 09:44
WALTHAM Mass.--26 Mar--PRNewswire/InfoQuest

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for the Company's New Coronavirus RT-PCR test. Clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this kit to detect SARS-CoV-2, the virus that causes COVID-19. PerkinElmer's RT-PCR test is marketed as an in vitro diagnostic (IVD) device by meeting the requirements of the European In Vitro Diagnostic Directive (IVDD) and is available in over 30 countries worldwide.

"Despite the challenging environment, our employees have demonstrated unwavering commitment over the past two months to combat this global pandemic," said Prahlad Singh, president and chief executive officer, PerkinElmer. "The breadth of PerkinElmer's total workflow solution puts us in a unique position to rapidly address the needs of our clinical diagnostics customers."

About PerkinElmer

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

More information can be found on PerkinElmer's official website:
http://ir.perkinelmer.com/news-releases/news-release-details/fda-provides-emergency-use-authorization-perkinelmer-covid-19
Photo   https://photos.prnasia.com/prnh/20200325/2760526-1
Caption: PerkinElmer's New Coronavirus RT-PCR test

Latest Press Release

Ansell Urges Global Priority For Supply Of Personal Protective Equipment

Ansell Limited, a global leader in protective solutions, is working with governments and health organizations worldwide to ensure unrestricted personal protective equipment (PPE) manufacture and supply is given top priority during the COVID-19...

Yiling Pharmacy Lianhua Qingwen has been approved by the Thai FDA

On March 31, Shijiazhuang Yiling Pharmaceutical Co., Ltd released a notice that they had received the approval of the modern herbal medicine registration issued by the Food and Drug Administration of Thailand. Lianhua Qingwen Capsule is recognized as in...

EW Nutrition Launches Industry-leading Webinar Series With Topical Antimicrobial Resistance Twin Sessions

Yesterday, German-based company EW Nutrition took a first step toward serving the animal production industry in these challenging times. The in-feed and on-farm solutions company has started a series of topical webinars on challenging issues such as...

Saxenda(R) Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity

Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda(R) (liraglutide 3.0 mg) in adolescents (aged 12–<18) with obesity.1 The study was accepted...

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use

Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020 Johnson & Johnson...

Related Topics